Trials / Completed
CompletedNCT02232633
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy. Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBI503 |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2017-12-14
- Completion
- 2017-12-14
- First posted
- 2014-09-05
- Last updated
- 2023-11-14
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02232633. Inclusion in this directory is not an endorsement.